Regen BioPharma Expands Management Team With The Addition Of New CFO Todd Caven

SAN DIEGO, CA--(Marketwired - February 17, 2015) - Regen BioPharma Inc. (OTC PINK: RGBP) announced that it has appointed Todd Caven to serve as the company's Chief Financial Officer. Mr. Caven is the cofounder of Saguaro Capital Partners, an Arizona based company that raises growth capital for medical device and technology companies throughout the United States., and Rock Ridge Enterprises LLC, a Minnesota-based Private Equity firm. Mr. Caven earned an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

Regen BioPharma's Chairman & CEO David Koos stated, "Mr. Caven is an accomplished executive with 30 years of experience in the areas of corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. We feel he will be a valuable addition to our management team and we look forward to his expected contributions to our future growth and business development."

The appointment of Mr. Caven is the second major hire made by the company since the beginning of 2015 following the appointment of Dr. Christine Ichim to the position of Director of Molecular Therapeutics.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTC PINK: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority owned by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. 


Contact:

Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404 Phone
619-330-2328 Fax
www.regenbiopharma.com 

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.